CLEOPATRA HOSPITALS GROUP S.A.E. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.16 EGP | -1.28% |
|
-0.65% | +30.51% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +30.51% | 187M | B- | ||
| -18.39% | 17.03B | B+ | ||
| +4.50% | 12.61B | B | ||
| +4.48% | 11.73B | B+ | ||
| +2.50% | 10.17B | B+ | ||
| -2.68% | 7.81B | A- | ||
| +22.36% | 7.25B | D | ||
| +4.12% | 6.66B | B- | ||
| +47.50% | 4.51B | - | ||
| -5.47% | 4.27B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- CLHO Stock
- Ratings Cleopatra Hospitals Group S.A.E.